Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript

Chronic myeloid leukemia (CML) with the rare fusion gene e19a2, encoding a p230 protein, has been described in patients with typical or rather aggressive clinical course. Although tyrosine kinase inhibitors (TKIs) induce a substantial cytogenetic and molecular response in all phases of CML, a minor...

Full description

Saved in:
Bibliographic Details
Main Authors: Marianna Greco, Giovanni Caocci, Giorgio La Nasa
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2013/871476
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849307749322588160
author Marianna Greco
Giovanni Caocci
Giorgio La Nasa
author_facet Marianna Greco
Giovanni Caocci
Giorgio La Nasa
author_sort Marianna Greco
collection DOAJ
description Chronic myeloid leukemia (CML) with the rare fusion gene e19a2, encoding a p230 protein, has been described in patients with typical or rather aggressive clinical course. Although tyrosine kinase inhibitors (TKIs) induce a substantial cytogenetic and molecular response in all phases of CML, a minority of p230 positive patients have been treated with TKIs. We report two cases of CML patients carrying the p230 transcript, who achieved fast and deep complete molecular response (CMR) after frontline treatment with nilotinib. Our results suggest the use of nilotinib as frontline agent for the treatment of this CML variant.
format Article
id doaj-art-27e1c3a9e4a548429480ef252679fbf9
institution Kabale University
issn 2090-6560
2090-6579
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Case Reports in Hematology
spelling doaj-art-27e1c3a9e4a548429480ef252679fbf92025-08-20T03:54:38ZengWileyCase Reports in Hematology2090-65602090-65792013-01-01201310.1155/2013/871476871476Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 TranscriptMarianna Greco0Giovanni Caocci1Giorgio La Nasa2Hematology Unit and Bone Marrow Transplantation Center, “R. Binaghi” Hospital, Via Is Guadazzonis 3, 09126 Cagliari, ItalyHematology Unit and Bone Marrow Transplantation Center, “R. Binaghi” Hospital, Via Is Guadazzonis 3, 09126 Cagliari, ItalyHematology Unit and Bone Marrow Transplantation Center, “R. Binaghi” Hospital, Via Is Guadazzonis 3, 09126 Cagliari, ItalyChronic myeloid leukemia (CML) with the rare fusion gene e19a2, encoding a p230 protein, has been described in patients with typical or rather aggressive clinical course. Although tyrosine kinase inhibitors (TKIs) induce a substantial cytogenetic and molecular response in all phases of CML, a minority of p230 positive patients have been treated with TKIs. We report two cases of CML patients carrying the p230 transcript, who achieved fast and deep complete molecular response (CMR) after frontline treatment with nilotinib. Our results suggest the use of nilotinib as frontline agent for the treatment of this CML variant.http://dx.doi.org/10.1155/2013/871476
spellingShingle Marianna Greco
Giovanni Caocci
Giorgio La Nasa
Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript
Case Reports in Hematology
title Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript
title_full Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript
title_fullStr Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript
title_full_unstemmed Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript
title_short Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript
title_sort early complete molecular response to first line nilotinib in two patients with chronic myeloid leukemia carrying the p230 transcript
url http://dx.doi.org/10.1155/2013/871476
work_keys_str_mv AT mariannagreco earlycompletemolecularresponsetofirstlinenilotinibintwopatientswithchronicmyeloidleukemiacarryingthep230transcript
AT giovannicaocci earlycompletemolecularresponsetofirstlinenilotinibintwopatientswithchronicmyeloidleukemiacarryingthep230transcript
AT giorgiolanasa earlycompletemolecularresponsetofirstlinenilotinibintwopatientswithchronicmyeloidleukemiacarryingthep230transcript